

Research Article

Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer

Aurelia Ada Guarini¹

1. Fondazione Istituto G. Giglio di Cefalù, Cefalù, Italy

To date, the virtual multidisciplinary tumor boards (vMTBs) are increasingly used to achieve high-quality treatment recommendations across health-care regions, which expands and develops the local MTB team to a regional or national expert network. This review describes the process of lung cancer-specific MTBs and the transition process from face-to-face tumor boards to virtual ones. The review also focuses on the project organization's description, advantages, and disadvantages. Semi-structured interviews identified five major themes for MTBs: current practice, attitudes, enablers, barriers, and benefits for the MTB. MTB teams exhibited positive responses to modeled data feedback. Virtualization reduces time spent for travel, allowing easier and timely patient discussions. This process requires a secure web platform to assure the respect of patients' privacy and presents the same unanswered problems. The implementation of vMTB also permits the implementation of networks especially in areas with geographical barriers facilitating interaction between large referral cancer centers and tertiary or community hospitals as well as easier access to clinical trial opportunities. Studies aimed to improve preparations, structure, and conduct of MTBs, research methods to monitor their performance, teamwork, and outcomes are also outlined in this article. Analysis of literature shows that MTB participants discuss 5–8 cases per meeting and that the use of a vMTB for lung cancer and in particular stage III NSCLC and complex stage IV cases is widely accepted by most health professionals. Despite still-existing gaps, overall vMTB represents a unique opportunity to optimize patient management in a patient-centered approach.

Introduction

Although significant improvement in the diagnostic and therapeutic armamentarium, lung cancer is still a major challenge worldwide with high disease-related morbidity and mortality [1]. To date, thoracic oncology care requires a complex multidisciplinary approach to assure the best quality of care [2]. Consequently, multidisciplinary tumor boards (MTB) are an essential component of contemporary cancer

care to the point that some countries established such an approach by law [3]. Australian authors deeply reviewed this issue [3].

The concept of MDT was first introduced in the UK in the 1990s, gaining more strength with the publication of the Calman-Hine plan in 1995, the radical reform of the UK's cancer services to ensure patients with cancer high and uniform standard of care, no matter where they might live [4,5]. A multidisciplinary tumor board (MTB) includes a set of diverse specialists such as thoracic surgeons, medical oncologists, radiation oncologists, radiologists, pneumologists, pathologists, and molecular biologists, often defined as "core team" [4]. The extended board may also encompass nuclear medicine specialists, nutritionists, palliative and rehabilitation care physicians, patients' advocacy representatives, research nurses, or other specialists, and in academic centers also students and post-doctoral fellows [6]. A cross-sectional qualitative interview study on breast and gynecological cancer MTD very recently explored patients' participation in tumor conferences at six cancer centers in Germany with conflicting results [7]. Besides the fact that half of the health providers had no experience in such settings, the study concluded that routine patients' participation in MTD was not feasible due to providers' common barriers and negative experiences. Only selected patients might be included in MTD looking for new opportunities and with positive experiences.

These meetings' primary purpose is to give the patient the best multidisciplinary treatment plan, shared between all the board members. The implementation of thoracic cancer-dedicated MTB aims to provide: a) best management through diagnostic and treatment recommendations generated according to a consensus-based method and supported by guidelines, b) appropriate and timely patient referrals, c) identification of clinical trials, d) increase the awareness of cancer research, and e) clinician education by sharing expertise from each discipline in an open environment, thereby promoting a broader knowledgebase for future care. Health governance studies on lung cancer management suggest that integrated and multidisciplinary care reduces barriers to treatment and variation in care, improves adherence to clinical guidelines, staging, and care coordination, significantly shortens the interval from diagnosis to treatment, and ultimately leading to a better patient experience and an increase in quality care for lung cancer patients [8,9].

BOARD VIRTUALIZATION AND TELEMEDICINE

The recent Covid-19 pandemic has altered the way to approach the patient [4]. A multidisciplinary care consultation has become more challenging to achieve; therefore, telemedicine's introduction may avoid any delay modifying care coordination in this time of crisis [10]. Besides minimizing the rate of infection and the spread of COVID-19 disease, the concept of vMTB is catching on to the design of pathways for cancer care because they may remove geographic barriers and facilitate clinical communication and decision making. Although many cancer centers and hospitals have local tumor boards, videoconferencing technology, boosted by the Covid-19 pandemic, has allowed the creation of virtual multidisciplinary tumor

boards (vMTB) [11,12]. These virtual meetings improve the collaboration between providers across geographic locations and institutions, giving proper allocation of health care resources and reducing time wasted for travel and related expenses [12,13].

The experience carried out at the University of Pittsburgh showed that meeting virtualization allows easy and efficient communication between vMTB participants at distant sites independently of the current pandemic state [12]. If adequately structured and implemented, a vMTB permits a network between high-volume academic institutions, general hospitals, and multiple satellites and community hospitals [12]. In the USA, the Duke Cancer Network created a secure web-based platform for lung cancer MTB involving a rural community and small hospital with a university-based cancer center 2 hours away as a referral center [13]. Any vMTB involved a median of ten participants that discussed no more than 2 cases per meeting, reporting adherence to guidelines and updated medical literature. This approach reduces time wasted for travel to reach the referral center and shortens time to case evaluation [13]. Such collaborative strategy strongly depends on efficient and effective communication between MTD team members [14]. To be efficient and effective, MTD requires a collaborative approach, appropriately leveraging the diverse expertise of NSCLC.

Criterion	Face-to-face MDT	Virtual Tumor Boards
Team	The members have already working relationships	Members sometimes do not know each other, trust and confidence may be difficult to establish, though members can take part to the meeting more easily if they are busy.
Attendance	The Leader can assess whether the relevant members are attending the meeting	Participation may be improved Reduction of time wasted to reach the coordinating center
Leader	The leader is known personally	Leader may change according to the specific task
Team Working	Tensions between the participants may be easily solved	The discussions may be less intense than in a face-to-face interaction
Scheduling	Meetings are usually scheduled at given day and time	Timing can be flexible, according to the need of the members
Personal growth and training	Good chances to improve interpersonal skills	Team members can interact with experts working far from their work places.

fig. 1 Comparison between traditional face-to-face multidisciplinary tumor boards and virtual tumor boards

MOLECULAR TUMOR BOARDS

Molecular tumor boards represent recent progress in multidisciplinary care [15]. These meetings include cancer experts equipped with genomic interpretation resources to deliver accurate and timely clinical

interpretations of complex genomic results for each patient within an institution or hospital network. Virtual molecular MTBs may provide an online forum for collaborative governance, provenance, and information sharing between experts outside a given hospital network with the potential to enhance MTB discussions. Knowledge sharing in VMTBs and communication with guideline-developing organizations can lead to progress evidenced by data harmonization across resources, crowd-sourced and expert-curated genomic assertions, and more informed and explainable usage of artificial intelligence. North American researchers reviewed the landscape of available tools, resources, and evidence to evaluate somatic and germline tumor variants in molecular MTB [15].

IMPACT ON CLINICAL OUTCOMES

Some evidence suggests that implementing MDT discussions improves patients' outcomes, i.e., pretreatment evaluation, proper staging, adequate treatment, quality of survivorship, and overall survival [12]. Specchia et al. very recently reported an umbrella review on MTB's impact on all types of cancer, reporting only one systematic review on lung cancer published several years ago in 2008 [13,14]. However, Australian researchers recently published a scoping review of current evidence for lung cancer MDT data collection and analysis and its impact on clinical outcome [18]. The authors identified thirteen studies that presented lung cancer MDT-related clinical outcomes. Three included MDTs from multiple tumor streams, while ten studies specifically focussed on lung cancer MDTs. Overall, eleven investigations, eight of which positive, examined the effect of MDT discussion on patients' clinical outcomes. Three studies included data from MDT records and the other three from medical patients' records. Five studies used institutional registries, and the remaining six extracted data from state or national administrative datasets, with some overlap. While MDT data collection is not well-defined, the importance of clinical audit and data feedback and the potential for real-time analysis to improve outcomes deserve further investigation. In 2001 a single-institution study in the USA reported changes in the pretreatment evaluation, diagnosis, and treatment plans in 20% to 50% of cases, mainly breast cancer, presented at MDTBs [19]. In 2007 the French Groupe d' Oncologie Thoracique Azuréen carried out a 1-year prospective study on 334 patients discussed during its multidisciplinary weekly meetings showing a 4.4% therapeutic discordance between the planned and the administered treatment [20]. In this series of patients median delay of treatment was 20 days, and the overall 1-year survival rate was lower for patients with MTD discordance without reaching statistical significance. A study carried out in Australia on 988 lung cancer patients registered in the cancer registry before 2011 showed how MTD discussion produced a significantly better receipt of radiotherapy among NSCLC patients with any stage (66% versus 33%, $p < .001$) and had significantly better receipt of chemotherapy among patients with stage IV NSCLC (46% versus 29%, $p < 0.001$) and palliative care (66% versus 53%, $p < 0.001$) as compared to patients without MDT discussion [21]. A logistic regression analysis

identified MDT discussion as an independent predictor of receiving radiotherapy, chemotherapy, and referral to palliative care but did not influence survival. **In 2012 a retrospective and comparative scientific report showed that in the UK, the** introduction of multidisciplinary care was associated with improved overall survival and reduced variation in survival data in various hospitals with MTB compared to the hospitals without such implementation [22]. In 2015 investigators at the MD Anderson Cancer Center and the Dana-Farber Cancer Institute published a survey on 1,198 physicians to explore MTB participation associations with patient survival and rate of clinical trial enrollment guideline-recommended care, and patient-reported quality [23]. This paper showed that physician engagement in MTB was associated with higher patient clinical trial participation and higher curative-intent surgery rates for stage I-II NSCLC but not with overall survival. In the same year, a national cohort study in Taiwan showed that the adjusted hazard ratio of death of stage III and IV NSCLC patients discussed at MDT was significantly lower at multivariate Cox proportional hazards model than that of patients without MDT discussion (HR = 0.87, 95% confidence interval = 0.84-0.90) [24]. Data were also analyzed for the propensity score as a control variable to reduce selection bias between patients with and without MDT care involvement. An Australian cohort study included 1197 cases discussed prospectively at MTB and analyzed for adjusted survival and referral to palliative care [25]. Survival of patients discussed at MTD was higher for all stages but IIIB as compared to patients not discussed, but referral to palliative care was not different. Overall adjusted survival analysis for the entire cohort showed improved survival at five years for patients discussed at MDT (HR 0.7, range 0.58-0.85, $p < 0.001$). However, the MTD group had a lower stage IV percentage (39.3% versus 56.1%). and an higher proportion of early-stage disease (stage I, 23.1% versus 9.7%, and stage II, 10.2% versus 4.8%, stage IIIA, 14.6% versus 6.3%). In 2018 a retrospective propensity score analysis was performed on 246 consecutive Italian patients who underwent surgery for NSCLC before or after implementing an MTB [26]. Patients discussed at the MTB showed more complete staging, better TMN classification, and a longer 1-year survival rate when compared with those who were not discussed at the MTB. In 2020 a German matched-pair analysis showed a positive impact of a higher number of multidisciplinary tumor boards on the clinical outcome [27]. Patients discussed at ≥ 3 MTD meetings had a significantly better overall survival than patients never discussed. In the same year, researchers in Taiwan carried out a retrospective study on 500 patients with stage III NSCLC to evaluate MTB's impact on survival. The median survival of patients discussed at MDT was statically longer than that of control patients (41.2 versus 25.7 months; $p = 0.018$) [28].

STAGE III NSCLC: A MTB PARADIGM

Due to the diagnostic and therapeutic algorithm's significant complexity, discussion of stage III NSCLC is the paradigm of a lung cancer MTB activity. Even if concurrent chemotherapy and radiotherapy plus

immunotherapy are currently considered the standard of care, however clinical real life, the approach is still heterogeneous across different specialists. An Italian cooperative group launched a 15-question web-based survey focusing on diagnostic/therapeutic of stage III to 421 health professionals, including pneumologists, thoracic surgeons, and radiation and medical oncologists [29]. Some discrepancies were present in clinical locally advanced NSCLC management: the lack of a regularly planned multidisciplinary tumor board, the use of upfront surgery in multi-station stage IIIA, and territorial diffusion of chemo-radiotherapy in unresectable locally advanced NSCLC. This analysis demonstrated good compliance with international guidelines in the diagnostic workup of locally advanced NSCLC and a relationship between high clinical experience and good clinical practice. In NSCLC, precise diagnosis and adequate staging are essential to ensure uniform allocation to the best treatment strategy, but these parameters may differ among MDTs. Dutch investigators showed a high grade of variability in T and N staging and treatment recommendation in a series of 110 patients with stage IIIA NSCLC among MDTs in different hospitals [30]. Agreement on clinical staging and treatment recommendations was rated using Randolph's free-marginal multi-rater kappa As a chance-adjusted index. Staging of T (T3 versus T4) and N (N1 versus N2) showed the highest variability, which reflected a wide range of additional diagnostics and influenced treatment recommendations as induction therapy and type.

Material and Methods

BARRIER AND FACILITATORS

Researchers at New South Wales, Australia, recently reported an exhaustive review on evidence-practice gaps in lung cancer MDC implementation [31]. Several pitfalls have been identified and grouped according to the patient, team, health service, and health system. The lack of control condition, variation in definitions, and outcome measures selected were research and evaluation gaps. These also included barriers to start pragmatic trials as a consequence of sample size and heterogeneity of MDTs. Patient-related gaps include insufficient patient-centered discussion, lack of patient evaluation of MDT meetings. Among MTB team-related pitfalls are difficulties in reaching consensus, variation in patient selection for team review, educational value, and communication within meetings. Health service and system gaps include quality outcomes and lack of cost data.

As a general rule, health professionals react positively to MDT participation and report various advantages from such strategy, but they also define areas for improvement, e.g., access to complete information and clearly identified roles for the different health professionals. A Swedish cross-sectional study explored participants' views on the meeting function, perceived benefits, and barriers among 244 health professionals [32]. Significant benefits from MTD included shared more accurate treatment recommendations, multidisciplinary evaluation, and adherence to clinical guidelines. Significant barriers to

a shared treatment recommendation were the need for supplementary investigations and inadequate pathology reports.

Investigators in Netherlands carried out semi-structured interviews to identify barriers and facilitators for implementing computerized clinical decision support systems (CCDSs) in managing lung cancer cases among twenty-six various health care professionals involved in MTBs [33]. Easy access to well-structured patients data, reduction of time needed to prepare cases, and MTD duration were primary facilitators for the use of CCDSs. The main barriers for adoption were incomplete or non-trustworthy output generated by the system and low capacity of MDT to adapt to local and contextual needs. Successful implementation depended on the reliability and adaptability of the CCDSs and key users' involvement in the implementation process. A Swedish qualitative study analyzed the views on enabling and impeding factors for multidisciplinary care of health professionals participating in a national wide vMTB on rare cancers [34]. Investigator examined the free-text opinions to identify three thematic categories: decision-making, organization, and responsibilities. These categories consisted of nine sub-categories that referred to, eg, Stone et al. reported a mixed-methods study on the clinical impact of modeled data feedback at lung cancer MTD based on pre and post-surveys and semi-structured interviews at three Australian cancer centers [35]. Results demonstrated agreement if they reached > 4 on a 5-point Likert scale. Most participants found modeled data easy to interpret, relevant to clinical practice and the MDT, and welcomed future regular data presentations.

QUALITY OF MTB

Measuring the quality of lung cancer MDTB is a challenging goal since the complexity of the lung cancer patient management renders this outcome challenging to reach [36]. A recent publication extensively reviewed this complex issue as regard to quality metrics [36]. To date few studies have explored this issue so far using a standardized approach. The quality of decision-making in MTD depends on the quality of records presented and team processes quality. MTD participants usually discuss 5-8 cases per meeting [35]. German investigators employed an adaptation of the observer rating scale Multidisciplinary Tumor Board Metric for the Observation of Decision-Making (MDT-MODE) to assess the quality of the presented information and team processes in 249 cases discussed at 29 MTBs [37]. Although the quality of different aspects of information differs significantly, this study reported high mean completeness of tumor records. However, quality psychosocial details and information on patient opinion were considered low and necessitating improvement. At mixed logistic regression analysis, uncertainty and discrepancies on medical treatment discussions were linked to a higher rate for more than one treatment recommendation. Time limitation per case also represented a negative factor. A Korean study retrospectively evaluated the level of agreement between IBM Watson for Oncology cognitive computing system and 405 lung MDT recommendations

concerning surgery, radiotherapy, chemo-radiotherapy, and palliative care [38]. Concordance between MDT and IBM Watson for Oncology occurred in 92.4% of all cases ($p < 0.001$), and concordance differed according to clinical stages. The agreement's strength was excellent in stage IV NSCLC (100%) and extensive disease small-cell lung carcinoma (100%). In stage I NSCLC, the agreement rate was high (92.4%). The concordance between MDT and artificial intelligence system was moderate in stage III NSCLC (80.8%) and relatively lower in stage II NSCLC (83.3%) and limited disease small-cell lung cancer (84.6%). The discrepancy was 12.3% in surgical decisions, 16.7% of radiotherapy prescriptions, and 11.6% chemo-radiotherapy choices. No discordance occurred in metastatic disease patients. However, investigators concluded that IBM Watson for Oncology was just an assisting tool in stage I-III NSCLC and limited disease SCLC. In this stage of the disease, the patient-doctor relationship and shared decision-making may be more critical.

LIABILITY

Health professionals participating in vMTB may undergo medico-legal obligations, including patient consent, privacy, professional liability, reporting dissenting views, and duty of care [3]. Most vMTBs employ a video platform that provides a secure web-site coupled with a secure teleconference platform to ensure patient confidentiality. Although evidence to formulate legal recommendations are scarce, authors identify the formative evidence that may guide the management of these issues in future MDTs.

TECHNOLOGY AND MTDS

The achievement of an accurate diagnosis and timely delivery of care demands high-quality MDT collaboration and coordination among participants. Computed clinical decision support systems (CDSSs) are significant technological progress and an integral component of today's health information technologies [39]. They assist with interpretation, diagnosis, and treatment. A CDSS can be embedded throughout the patient safety continuum providing reminders, recommendations, and alerts to health care providers. Although CDSSs may reduce medical errors and improve patient outcomes, they have fallen short of their full potential. User acceptance has been identified as one of the potential reasons for this shortfall. Investigators of the University of Carolina at Chapel Hill, USA, reported a critical analysis of health professional barriers to the adoption of computed clinical decision support systems [40]. Health professional non-acceptation of CDSS was the main barrier to technology implementation, with a possible negative effect on patients' health and well-being. The incorporation of CDSSs based on user needs/expectations in the assistance-engage model may improve the tools use. Using CCDs in lung cancer, MTBs may increase the efficiency of workflows supporting participants in elaborating a shared conceptual workflow of a patient case. CCDs may help the MTB to evaluate the completeness of collected diagnostic data, stratification for the right personalized therapy according to the clinical and radiological stage and other treatment-influencing factors, and adapt care management strategies when needed. CDSSs have not

been currently included in the MTB decision-making workflow, which hampers their clinical practice impact. A group of Dutch and UK researchers designed a CDSS for multidisciplinary decision-making in lung cancer to support the goals mentioned earlier by presenting relevant clinical data in line with the MDT members' existing mental model structures [41]. Results achieved in simulated lung cancer MTBs showed that CDSSs help participants in their capacity to adjust diagnosis, staging, and classification according to the TNM system. It enabled cross-validation of diagnostic findings, surfaced discordance between diagnostic tests and facilitated cancer staging according to the diagnostic evidence, and spotting contra-indications for personalized treatment selection.




fig. 2 Map indicating cancer centers, academic hospitals, and tertiary centers participating in the network virtual multidisciplinary tumor board. Arrows indicate usual patient referral dynamics and bullets represent all centers with an oncology unit according to patients volume and type of institution

Results

NETWORK MBT EXPERIENCE

The Covid-19 pandemic has altered the way to approach the patient, and this latter has found some limitations with clinical resources [42]. Therefore, a multidisciplinary care consultation has become more difficult. In this situation, a patient with cancer would receive a multidisciplinary consultation within several weeks. As above stated, a vMTB allowed the connection between large referral cancer centers and peripheral tertiary or community hospitals, often quite far from each other in North Carolina, USA [12].

On the other hand, an efficient vMTB organization may be essential to sustain oncological networks, especially in vast geographical areas with mobility problems. As shown in Figure n. 3, many academic and cancer centers in Sicily, Italy, collaborate closely with tertiary and community hospitals, thanks to telemedicine and vMTB. The Covid-19 pandemic improved this kind of cooperation to offer a punctual and prospective multidisciplinary clinical decision. A clinical observation study on the efficacy and efficiency of vMTB started in July 2020 [43]. Subspecialty cancer-specific tumor boards are held at 06.30 pm once a week or twice a month, according to the availability of clinical cases and the participants' needs. The vMTB attendees include medical oncologists, radiation oncologists, surgeons, pathologists, molecular biologists, radiologists, nuclear medicine specialists, patients' advocacy members, and a case manager. All together represent the "core team," other specialists can also participate depending on the tumor board's type and specialty; some vMTB may also include nutritionists, palliative care physicians, and research nurses. A useful tumor board also requires a leader to chair and run the meetings. The leader should facilitate the decision-making process by allowing the team discussion and information sharing. A coordinator will also be useful to plan the web conferences and coordinate all the members of the vMTB. Meetings occur on a web conferencing platform, provided with a specific license, with secure patient data protection and storage. The platform allows geo-localization of clinical trials, matching recommendations with updated guidelines, and access to relevant updated medical literature. The attendees invited by the guest can only attend the conference; the members can access the web platform via the URL link provided to access the meeting. Patient records are anonymized and presented by the primary oncology provider through the platform's presentation (Figure n.). Patients have been previously informed by their doctors and have signed informed consent. The MTB workflow encompasses sending cases by the presenting physician to the administrator who collates and lists all the points on a platform's password-protected room. The clinical cases are initially presented by the patient's primary physician with relevant radiologic and pathologic findings and then discussed to obtain a final recommendation proposal. At the end of each case discussion, our web platform allows electronic and anonymous voting of the clinical decisions proposed during the meeting. If a consensus $\geq 75\%$ of participants is achieved, each patient's chart is filled with the board's final recommendations employing the platform drop-down menu. Patients' data and decisions are then stored and may be rediscussed as follow-up progresses. The shared recommendations can be scanned and uploaded into the electronic health record system. In our experience, lung tumor board meetings usually regard the multimodality approach to stage III lung cancer, an advanced-stage disease with molecular drivers, and clinical trial opportunities. Virtual MTB organizers constituted a steering committee to validate decisions and promote scientific research (picture 2). After six months, a survey on the acceptability, appropriateness, and feasibility of vMTB was e-distributed to 74 health professionals who have been

attending the meetings. We found that the majority (95%) of respondents reported that the transition to a virtual MTD was feasible and acceptable, providing the same standard of care as face-to-face MDTs. The survey positively highlighted the impact of the project as follows: 91% on optimization of clinical information flows; 96% on equity of care; 88% on collaboration among specialists and method standardization; 77% on data security, tracking, storage, and reuse. Currently, the scientific opinions expressed have been verified as adhering to the guidelines and scientific evidence available in all the cases examined.

An Australian study explored the possibility to develop and implement a standardized template for lung cancer MTB to provide clear clinical information and treatment recommendations to all participants and general practitioners [44]. This approach could also ensure timely information share between tertiary and primary care centers. The study involved 41 physicians and researchers developing a template and implementation strategy and employed a mixed-method study design using structured interviews with 61 participating general practitioners. The MDT-reporting template appears to be a feasible way of providing clinical information to GPs following patient presentation at a lung cancer MDT meeting. Ninety-five percent of general practitioners strongly agreed that the standardized template offered useful and relevant information, received on time (90%) and that the information was easy to interpret and communicate to the patient (84%). Implementation process data show that the pre-implementation stage's investment to integrate the template into standard work practices was critical in the successful implementation.

IMPLEMENTATION OF VIRTUAL MTBs

Overall, vMTB may be implemented if some objective quality indicators are provided. The UK and Swedish researchers developed and validated a scientific instrument called “A Tumor Leadership Assessment instrument” (ATLAS) to assess and capture

leadership and chairing skills in the cancer MTB setting [45,46]. ATLAS develops the observational assessment within 12 domains: time management, case prioritization, team involvement, discussion climate, and clarity of treatment recommendations. This validated instrument can define strengths, weaknesses, and opportunities for team development.

The time needed to prepare the clinical case represents another critical pha

se in the vMTB process: the case submission should occur at least 24 hours before the meeting to allow the participants to prepare the discussion adequately. The members of the conference should be able to share their computer screen. In this manner, radiologists can share patients' scans easily. At the same time, the pathologists may be able to share reports, stains, and other information.

An essential difference between regular face-to-face sessions and vMTB is the amount of time spent in clinical case discussions. Irish analysts found that web conferences are associated with a greater time spent per case (147%), increased participants' turn duration, and total attendance was resulting in decreased numbers of total participants per minute [47]. The most challenging clinical cases should be discussed first, when all the attendees are available, and each case should be presented within a given time. The data recording should be goal-oriented: all the participants should have access to patients' information and may be able to edit them. The data recording should be goal-oriented: all the participants should have access to patients' data and may be able to edit them. Some web applications like Research Electronic Data Capture (REDCap) are used to document the vMTB meetings, register patient information such as diagnosis, histopathology, and the board's decisions [48].

Conclusions

Virtual MTB can extend and facilitate the advantages of traditional tumor boards. Besides the fact that in the COVID-19 pandemic era, they may represent useful tools to reduce interpersonal contact and the virus spread, virtualization allows the health-providers to participate and communicate in a much more manageable way since time spent for travel is undo facilitating the involvement. However, virtual meetings may not necessarily substitute for the traditional face-to-face tumor boards because there are still some advantages when the participating members get to know each other personally. The interaction between diverse specialists with information and decision sharing is fundamental for an optimal clinical recommendation.

Virtual MTB may overcome the traditional tumor boards' hurdles: a) the participating members' engagement to the web conferences is enhanced; b) geographical barriers are eliminated; c) patients receive a multidisciplinary care treatment plan without delay; d) data can be analyzed automatically and stored in the cloud-based platform; e) clinical trial referral is improved, and f) scientific research encouraged. Although telemedicine has facilitated the patient's management, more studies are needed to validate this new clinical practice. MDT data collection and linkage are not standardized and not routine with few exceptions, although data collection and feedback are recommended explicitly by at least one statutory body. In conclusion vMTB permit optimal per-patient decision-making as treatment options become ever more specialized in the era of biomarker-driven therapeutic strategies.

Declarations

Funding: The author(s) received no specific funding for this work.

Potential competing interests: The author(s) declared that no potential competing interests exist.